Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Feasibility Study of [11C]Acetate Positron Emission Tomography (PET) as an Indicator of Early Response to Rapamycin in Lymphangioleiomyomatosis (LAM) Patients

NCT05467397 is registered in ClinicalTrials.gov with Brigham and Women's Hospital as lead sponsor.

NCT NCT05467397
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05467397 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Feasibility Study of [11C]Acetate Positron Emission Tomography (PET) as an Indicator of Early Response to Rapamycin in Lymphangioleiomyomatosis (LAM) Patients
Lead sponsor
Brigham and Women's Hospital
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
August 30, 2021
Completion date
June 30, 2026
Enrollment
7 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lymphangioleiomyomatosis, tuberous sclerosis complex